Merck and Mayo Clinic Partner to Accelerate AI-Driven Drug Discovery

Merck and Mayo Clinic have announced a strategic research collaboration aimed at leveraging artificial intelligence (AI), advanced analytics, and multimodal clinical data to enhance drug discovery and precision medicine. The partnership integrates Mayo Clinic’s extensive clinical and genomic datasets with Merck’s AI and machine learning capabilities to improve disease understanding, target identification, and early development decisions.

Platform Integration Enhances Innovation:

Through the Mayo Clinic Platform, Merck gains secure access to de-identified clinical data, molecular information, and biorepositories, combined with AI-enabled analytics. This integration allows Merck to validate AI models effectively and translate research insights into actionable drug development strategies, marking a significant step toward faster, data-driven innovation.

Focus on High-Need Therapeutic Areas:

The collaboration will initially target gastroenterology, dermatology, and neurology, focusing on inflammatory bowel disease, atopic dermatitis, and multiple sclerosis. By applying advanced AI and multimodal approaches in these high-priority areas, the partnership aims to accelerate the development of more precise and effective therapies.